Actinium Pharmaceuticals Inc at Guggenheim Healthcare Talks: Radiopharmaceuticals Day Transcript
All right, let's get our next session started. Once again, I'm Charles Zhu, Senior Biotech Analyst here at Guggenheim Securities. Joining us for our next session will be Actinium Pharmaceuticals. Thank you Sandesh as well as Madhuri for joining us here today. Perhaps just to get us started off, would you like to run through and introduce your company, your platform, and pipeline?
Sure. Absolutely. Thanks, Charles. So we are a public company, so a little SEC disclaimer there. Why don't we just skip through this slide, please?
All right. So look, we are at a radio conference and we do have a radiopharmaceutical technology. But the case I'm going to make for many of you is for us, the real story is about what we could do with the clinical data that this company has generated and has made public in the last four or five months. And on that basis, I would argue for us that come to work at Actinium. We are an AML story and that we have one of the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
